NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 166,011 Shares

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 166,011 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the sale, the insider now owns 11,150,461 shares of the company's stock, valued at approximately $283,110,204.79. This represents a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total value of $834,486.84.
• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total value of $213,420.60.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded up $0.02 on Monday, hitting $24.71. The stock had a trading volume of 771,794 shares, compared to its average volume of 366,977. The company's 50-day moving average is $20.67 and its two-hundred day moving average is $18.75. NewAmsterdam Pharma has a one year low of $10.12 and a one year high of $27.29.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NAMS. Piper Sandler restated an "overweight" rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada restated an "outperform" rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $36.20.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently added to or reduced their stakes in NAMS. Barclays PLC grew its holdings in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after acquiring an additional 7,199 shares during the period. Geode Capital Management LLC lifted its holdings in shares of NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company's stock valued at $1,433,000 after purchasing an additional 1,399 shares in the last quarter. M&T Bank Corp boosted its position in shares of NewAmsterdam Pharma by 54.1% in the third quarter. M&T Bank Corp now owns 27,328 shares of the company's stock worth $454,000 after buying an additional 9,593 shares during the period. Frazier Life Sciences Management L.P. grew its holdings in shares of NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company's stock valued at $213,396,000 after buying an additional 628,251 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of NewAmsterdam Pharma during the third quarter valued at $187,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.